After progression, the following treatment options are recommended: fulvestrant +/− CDK 4/6 inhibitor [13,14,15], AI + CDK 4/6 inhibitor (if previously not received CDK 4/6 inhibitor), alpelisib (PI3K inhibitor) + ET for those with tumor with PIK3CA mutations [16], capivasertib + fulvestrant for patients with PIK3CA- or-AKT1 activating mutations or PTEN alterations [17], elascentrant for estrogen receptor 1 (ESR1)-activating mutations [18], everolimus (mTOR inhibitor) + ET [19], AI +/− fulvestrant [20], olaparib or talazoparib for BRCA1/2 mutation carriers [21], or CT. Here, ESR1 is linked to neoplasm.